Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

The FDA Approval of Regeneron's EYLEA Is Important
The PANORAMA Trial of EYLEA for Diabetic Retinopathy
The United States Food and Drug Administration (FDA) has approved Regeneron’s (REGN) product EYLEA® (aflibercept) Injection for all stages of diabetic retinopathy. This approval is important. The data demonstrated from the PANORAMA trial showed EYLEA’s capability of reducing the risk of blindness in millions of people with diabetic retinopathy.

That is the message David Brown, M.D., F.A.C.S., an investigator for . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.